Signalling pathways and adhesion molecules as targets for antiangiogenesis therapy in tumors

Advances in Experimental Medicine and Biology

Volumn 610, Issue , 2008, Pages 74-87

  Bazzoni, Gianfranco ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CADHERIN; CELL ADHESION MOLECULE; FLUOROURACIL; INTEGRIN; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CELL ADHESION; COLORECTAL CANCER; ENDOTHELIUM CELL; HUMAN; LYMPHANGIOGENESIS; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR; ANIMAL; ENDOTHELIUM; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CADHERINS; CELL ADHESION; CELL ADHESION MOLECULES; ENDOTHELIUM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47949087711     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-73898-7_6     Document Type: Review

References (63)

1. Achen, M. G.; B. K. McColl and S. A. Stacker (2005). Focus on lymphangiogenesis in tumor disease. Cancer Cell 7: 121-7.
2. Alitalo, K. and P. Carmeliet (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219-27.
3. Alitalo, K.; T. Tammela and T. V. Petrova (2005). Lymphangiogenesis in development and human disease. Nature 438: 946-53.
4. Bader, B. L.; H. Rayburn; D. Crowley and R. O. Hynes (1998). Extensive vasculogenesis, angio-genesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95: 507-19.
5. Bazzoni, G. (2003). The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 15: 525-30.
6. Bazzoni, G. and E. Dejana (2004). Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84: 869-901.
7. Bazzoni, G., E. Dejana and M. G. Lampugnani (1999). Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths. Curr Opin Cell Biol 11: 573-81.
8. Cambier, S.; S. Gline; D. Mu; R. Collins; J. Araya; G. Dolganov; S. Einheber; N. Boudreau and S. L. Nishimura (2005). Integrin alpha(v)beta8- mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am J Pathol 166: 1883-94.
9. Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-6.
10. Carmeliet, P.; M. G. Lampugnani; L. Moons; F. Breviario; V. Compernolle; F. Bono; G. Balconi; R. Spagnuolo; B. Oostuyse; M. Dewerchin; A. Zanetti; A. Angellilo; V. Mattot; D. Nuyens; E. Lutgens; F. Clotman; M. C. de Ruiter; A. Gittenberger-de Groot; R. Poelmann; F. Lupu; J. M. Herbert; D. Collen and E. Dejana (1999). Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147-57.
11. Carmeliet, P. and M. Tessier-Lavigne (2005). Common mechanisms of nerve and blood vessel wiring. Nature 436: 193-200.
12. Cattelino, A.; S. Liebner; R. Gallini; A. Zanetti; G. Balconi; A. Corsi; P. Bianco; H. Wolburg; R. Moore; B. Oreda; R. Kemler and E. Dejana (2003). The conditional inactivation of the beta-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J. Cell Biol 162: 1111-22.
13. Cavallaro, U.; S. Liebner and E. Dejana (2006). Endothelial cadherins and tumor angiogenesis. Exp Cell Res 312: 659-67.
14. Cera, M. R.; A. Del Prete; A. Vecchi; M. Corada; I. Martin-Padura; T. Motoike; P. Tonetti; G. Bazzoni; W. Vermi; F. Gentili; S. Bernasconi; T. N. Sato A. Mantovani and E. Dejana (2004). Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A-deficient mice. J. Clin Invest 114: 729-38.
15. Corada, M.; F. Liao; M. Lindgren; M. G. Lampugnani; F. Breviario; R. Frank; W. A. Muller; D. J. Hicklin P. Bohlen and E. Dejana (2001). Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 97: 1679-84.
16. Coultas, L., K. Chawengsaksophak and J. Rossant (2005). Endothelial cells and VEGF in vascular development. Nature 438: 937:45.
17. Dejana, E. (2004). Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 5: 261-70.
18. Dumont, D. J.; L. Jussila; J. Taipale; A. Lymboussaki; T. Mustonen; K. Pajusola M. Breitman and K. Alitalo (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282: 946-9.
19. Fassler, R. and M. Meyer (1995). Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev 9: 1896-908.
20. Ferrara, N. and R. S. Kerbel (2005). Angiogenesis as a therapeutic target. Nature 438: 967-74.
21. Fong, G. H.; J. Rossant; M. Gertsenstein and M. L. Breitman (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
22. Francis, S. E.; K. L. Goh; K. Hodivala-Dilke; B. L. Bader; M. Stark D. Davidson and R. O. Hynes (2002). Central roles of alpha5betal integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vase Biol 22: 927-33.
23. Gerhardt, H.; M. Golding; M. Fruttiger; C. Ruhrberg; A. Lundkvist; A. Abramsson; M. Jeltsch; C. Mitchell; K. Alitalo, D. Shima and C. Betsholtz (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol 161: 1163-77.
24. Hiratsuka, S.; O. Minowa; J. Kuno T. Noda and M. Shibuya (1998). Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 95: 9349-54.
25. Hodivala-Dilke, K. M.; K. P. McHugh; D. A. Tsakiris; H. Rayburn; D. Crowley; M. Ullman-Cullere; F. P. Ross; B. S. Coller; S. Teitelbaum and R. O. Hynes (1999). Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin Invest 103: 229-38.
26. Hurwitz, H., L. Fehrenbacher; W. Novotny; T. Cartwright; J. Hainsworth; W. Heim; J. Berlin; A. Baron; S. Griffing; E. Holmgren; N. Ferrara; G. Fyfe; B. Rogers R. Ross and F. Kabbinavar (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-42.
27. Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-87.
28. Karkkainen, M. J.; P. Haiko; K. Sainio; J. Partanen; J. Taipale; T. V Petrova; M. Jeltsch; D. G. Jackson; M. Talikka; H. Rauvala; C. Betsholtz and K. Alitalo (2004). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5: 74-80.
29. Karpanen, T.; M. Egeblad; M. J. Karkkainen; H. Kubo; S. Yla-Herttuala; M. Jaattela and K. Alitalo (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intral-ymphatic tumor growth. Cancer Res 61: 1786-90.
30. Lampugnani, M. G.; A. Zanetti; M. Corada; T. Takahashi; G. Balconi; F. Breviario; F. Orsenigo; A. Cattelino; R. Kemler T. O. Daniel and E. Dejana (2003). Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol 161: 793-804.
31. Liebner, S.; A. Cattelino; R. Gallini; N. Rudini; M. Iurlaro; S. Piccolo and E. Dejana (2004). Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion develop-ment in the mouse. J. Cell Biol 166: 359-67.
32. Lindahl, P.; B. R. Johansson; P. Leveen and C. Betsholtz (1997). Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-5.
33. Lyden, D.; K. Hattori; S. Dias; C. Costa; P. Blaikie; L. Butros; A. Chadburn; B. Heissig; W. Marks; L. Witte; Y. Wu; D. Hicklin; Z. Zhu; N. R. Hackett; R. G. Crystal; M. A. Moore; K. A. Hajjar; K. Manova; R. Benezra and S. Rafii (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-201.
34. Maeshima, Y.; A. Sudhakar; J. C. Lively; K. Ueki; S. Kharbanda; C. R. Kahn; N. Sonenberg; R. O. Hynes and R. Kalluri (2002). Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295: 140-3.
35. Maisonpierre, P. C.; C. Suri; P. F. Jones; S. Bartunkova; S. J. Wiegand; C. Radziejewski; D. Compton; J. McClain; T. H. Aldrich; N. Papadopoulos; T. J. Daly; S. Davis; T. N. Sato and G. D. Yancopoulos (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
36. McCarty, J. H.; R. A. Monahan-Earley; L. F. Brown; M. Keller; H. Gerhardt; K. Rubin; M. Shani; H. F. Dvorak; H. Wolburg; B. L. Bader A. M. Dvorak and R. O. Hynes (2002). Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol 22: 7667-77.
37. Nikolopoulos, S. N.; P. Blaikie; T. Yoshioka; W. Guo and F. G. Giancotti (2004). Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6: 471-83.
38. Nitta, T.; M. Hata; S. Gotoh; Y Seo; H. Sasaki; N. Hashimoto; M. Furuse and S. Tsukita (2003). Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: 653-60.
39. O'Reilly, M. S.; T. Boehm; Y Shing; N. Fukai; G. Vasios; W. S. Lane; E. Flynn; J. R. Birkhead; B. R. Olsen and J. Folkman (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-85.
40. Oliner, J.; H. Min; J. Leal; D. Yu; S. Rao; E. You; X. Tang; H. Kim; S. Meyer; S. J. Han; N. Hawkins; R. Rosenfeld; E. Davy; K. Graham; F. Jacobsen; S. Stevenson; J. Ho; Q. Chen; T. Hartmann; M. Michaels; M. Kelley; L. Li; K. Sitney; F. Martin; J. R. Sun; N. Zhang; J. Lu; J. Estrada; R. Kumar; A. Coxon; S. Kaufman; J. Pretorius; S. Scully; R. Cattley; M. Payton; S. Coats; L. Nguyen; B. Desilva; A. Ndifor; I. Hayward; R. Radinsky, T. Boone and R. Kendall (2004). Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-16.
41. Pasquale, E. B. (2005). Eph receptor signalling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 6: 462-75.
42. Pike, S. E.; L. Yao; K. D. Jones; B. Cherney; E. Appella; K. Sakaguchi; H. Nakhasi; J. Teruya-Feldstein; P. Wirth; G. Gupta and G. Tosato (1998). Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188: 2349-56.
43. Reynolds, L. E.; L. Wyder; J. C. Lively; D. Taverna; S. D. Robinson; X. Huang; D. Sheppard R. O. Hynes and K. M. Hodivala-Dilke (2002). Enhanced pathological angiogenesis in mice lack-ing beta3 integrin or beta3 and beta5 integrins. Nat Med 8: 27-34.
44. Saitou, M.; M. Furuse; H. Sasaki; J. D. Schulzke; M. Fromm; H. Takano; T. Noda and S. Tsukita (2000). Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 11:4131-42.
45. Serini, G.; D. Valdembri and F. Bussolino (2006). Integrins and angiogenesis: a sticky business. Exp Cell Res 312: 651-8.
46. Shalaby, F.; J. Rossant; T. P. Yamaguchi; M. Gertsenstein; X. F. Wu; M. L. Breitman and A. C. Schuh (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-6.
47. Shibuya, M. and L. Claesson-Welsh (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-60.
48. Silvestre, J. S.; C. Thery, G. Hamard; J. Boddaert; B. Aguilar; A. Delcayre; C. Houbron; R. Tamarat; O. Blanc-Brude; S. Heeneman; M. Clergue; M. Duriez; R. Merval; B. Levy; A. Tedgui; S. Amigorena and Z. Mallat (2005). Lactadherin promotes VEGF-dependent neovas-cularization. Nat Med 11: 499-506.
49. Soldi, R.; S. Mitola; M. Strasly; P. Defilippi; G. Tarone and F. Bussolino (1999). Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 18: 882-92.
50. Stacker, S. A.; C. Caesar; M. E. Baldwin; G. E. Thornton; R. A. Williams; R. Prevo; D. G. Jackson; S. Nishikawa; H. Kubo and M. G. Achen (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-91.
51. Stephens, L. E.; A. E. Sutherland; I. V. Klimanskaya; A. Andrieux; J. Meneses R. A. Pedersen and C. H. Damsky (1995). Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev 9: 1883-95.
52. Stupack, D. G.; X. S. Puente; S. Boutsaboualoy C. M. Storgard and D. A. Cheresh (2001). Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155: 459-70.
53. Sund, M.; Y. Hamano; H. Sugimoto; A. Sudhakar; M. Soubasakos; U. Yerramalla; L. E. Benjamin; J. Lawler; M. Kieran A. Shah and R. Kalluri (2005). Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A 102: 2934-9.
54. Suri, C.; P. F. Jones; S. Patan; S. Bartunkova; P. C. Maisonpierre; S. Davis T. N. Sato and G. D. Yancopoulos (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-80.
55. Takahashi, T., H. Ueno and M. Shibuya (1999). VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-30.
56. Tucker, G. C. (2003). Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4: 722-31.
57. van der Neut, R.; P. Krimpenfort; J. Calafat, C. M. Niessen and A. Sonnenberg (1996). Epithelial detachment due to absence of hemidesmosomes in integrin beta 4 null mice. Nat Genet 13: 16:55-9.
58. Wallez, Y, I. Vilgrain and P. Huber (2006). Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16: 55-9.
59. Watanabe, K.; Y Hasegawa; H. Yamashita; K. Shimizu; Y Ding; M. Abe; H. Ohta; K. Imagawa; K. Hojo; H. Maki, H. Sonoda and Y. Sato (2004). Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 114: 898-907.
60. Yancopoulos, G. D.; S. Davis; N. W. Gale; J. S. Rudge; S. J. Wiegand and J. Holash (2000). Vascular-specific growth factors and blood vessel formation. Nature 407: 242-8.
61. Yang, J. T.; H. Rayburn and R. O. Hynes (1993). Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119: 1093-105.
62. Zakarija, A. and G. Soff (2005). Update on angiogenesis inhibitors. Curr Opin Oncol 17: 5789-83.
63. Zhu, J.; K. Motejlek; D. Wang; K. Zang, A. Schmidt and L. F. Reichardt (2002). beta8 integrins are required for vascular morphogenesis in mouse embryos. Development 129: 2891-903.